Fatih Ergül
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatih Ergül has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Guney
Konya Şehir Hastanesi
7 shared publications - Beyza Doğan
Department of Nephrology, University Health of Sciences, Konya City Hospital, Konya
5 shared publications - Süleyman Karaköse
Nephrology Clinic, Konya City Hospital, Health Sciences University, 42020 Konya, Türkiye
5 shared publications - Mikail Dağ
Konya Şehir Hastanesi
4 shared publications - Edip Erkuş
Sağlık Bilimleri Üniversitesi Konya Eğitim ve Araştırma Hastanesi
2 shared publications Mikail Dağ
Department of Nephrology University of Health Sciences Konya City Hospital Turkey
2 shared publications
Latest Publications
- 18 August 2026
- Published by Elsevier in Transplantation Proceedings
Long-Term Outcomes of Renal Transplantation in Patients with Cystinosis
- 18 August 2026
- Published by Elsevier in Transplantation Proceedings
Long-Term Outcomes of Renal Transplantation in Patients with Cystinosis
- 9 March 2026
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 65 (1) , 25-32
The frequency of irritable bowel syndrome in predialysis patients with chronic kidney disease and its associated factors
Aim: This study aimed to determine the frequency of irritable bowel syndrome (IBS) and associated factors, as well as the levels of depression and anxiety, in patients with chronic kidney disease (CKD) not receiving dialysis. It also aimed to explore potential measures to improve quality of life.Materials and Methods: Patients with stage III–V predialysis CKD were assessed for IBS based on the Rome IV criteria. Anxiety and depression levels were evaluated using the Hamilton Anxiety and Depression Rating Scales. Patients were divided into two groups based on the presence of IBS.Results: Among 154 patients, 33 (21.4%) had IBS and 121 (78.6%) did not. In the IBS group, 5 patients had no anxiety, 14 had mild, and 14 had major anxiety. In the non-IBS group, 44 had no anxiety, 52 had mild, and 25 had major anxiety. A significant difference in anxiety levels was observed between the two groups, but no significant difference was found in depression levels. Subgroup analysis also revealed a significant difference in anxiety. While no significant differences were found regarding the use of phosphate binders, calcium channel blockers, or beta-blockers, ACE inhibitor/ARB use was significantly higher in the IBS group.Conclusion: IBS was more frequent in predialysis CKD patients compared to the general population. Anxiety was more common in IBS patients, and ACEI/ARB use was associated with increased IBS frequency. IBS can begin before dialysis, so it should be considered when managing treatment in predialysis CKD patients.
- 9 March 2026
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 65 (1) , 25-32
The frequency of irritable bowel syndrome in predialysis patients with chronic kidney disease and its associated factors
Aim: This study aimed to determine the frequency of irritable bowel syndrome (IBS) and associated factors, as well as the levels of depression and anxiety, in patients with chronic kidney disease (CKD) not receiving dialysis. It also aimed to explore potential measures to improve quality of life.Materials and Methods: Patients with stage III–V predialysis CKD were assessed for IBS based on the Rome IV criteria. Anxiety and depression levels were evaluated using the Hamilton Anxiety and Depression Rating Scales. Patients were divided into two groups based on the presence of IBS.Results: Among 154 patients, 33 (21.4%) had IBS and 121 (78.6%) did not. In the IBS group, 5 patients had no anxiety, 14 had mild, and 14 had major anxiety. In the non-IBS group, 44 had no anxiety, 52 had mild, and 25 had major anxiety. A significant difference in anxiety levels was observed between the two groups, but no significant difference was found in depression levels. Subgroup analysis also revealed a significant difference in anxiety. While no significant differences were found regarding the use of phosphate binders, calcium channel blockers, or beta-blockers, ACE inhibitor/ARB use was significantly higher in the IBS group.Conclusion: IBS was more frequent in predialysis CKD patients compared to the general population. Anxiety was more common in IBS patients, and ACEI/ARB use was associated with increased IBS frequency. IBS can begin before dialysis, so it should be considered when managing treatment in predialysis CKD patients.
- Open Access
- 20 February 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 14-19
Effect of iron sucrose on intradialytic blood pressure in patients receiving maintenance hemodialysis treatment
Aims: There are studies showing that IV iron sucrose is vasoactive and causes changes in intradialytic blood pressure in hemodialysis patients. Intradialytic hypotension has been associated with vascular thrombosis, inadequate dialysis, and increased mortality. Intradialytic hypertension, has been shown in some studies to be associated with increased cardiovascular mortality and an increase in the frequency of hospitalization. In this study, we aimed to investigate the effect of iron sucrose on intradialytic blood pressure in hemodialysis patients.Methods: In this study, 59 patients undergoing hemodialysis three times a week had their blood pressure measured before hemodialysis and recorded at minute 0. 100 mg/5 ml iron sucrose was administered as an IV infusion during the first 30 minutes of dialysis treatment, and blood pressure was measured and recorded every 30 minutes. The same patient's blood pressure was measured every 30 minutes during the next hemodialysis session without iron sucrose treatment. Results: Intradialytic hypotension developed in two different patient; one patient in the session in which iron sucrose was given and one in the session in which iron sucrose was not given. There was no significant difference in intradialytic hypertension between the groups according to all three definitions of intradialytic hypertension (p=0.134; 0.523; and 1, respectively).Conclusion: We found that iron sucrose administration does not cause both intradialytic hypotension and intradialytic hypertension.
- 20 February 2026
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 7 (1) , 14-19
Open AccessEffect of iron sucrose on intradialytic blood pressure in patients receiving maintenance hemodialysis treatment
Aims: There are studies showing that IV iron sucrose is vasoactive and causes changes in intradialytic blood pressure in hemodialysis patients. Intradialytic hypotension has been associated with vascular thrombosis, inadequate dialysis, and increased mortality. Intradialytic hypertension, has been shown in some studies to be associated with increased cardiovascular mortality and an increase in the frequency of hospitalization. In this study, we aimed to investigate the effect of iron sucrose on intradialytic blood pressure in hemodialysis patients.Methods: In this study, 59 patients undergoing hemodialysis three times a week had their blood pressure measured before hemodialysis and recorded at minute 0. 100 mg/5 ml iron sucrose was administered as an IV infusion during the first 30 minutes of dialysis treatment, and blood pressure was measured and recorded every 30 minutes. The same patient's blood pressure was measured every 30 minutes during the next hemodialysis session without iron sucrose treatment. Results: Intradialytic hypotension developed in two different patient; one patient in the session in which iron sucrose was given and one in the session in which iron sucrose was not given. There was no significant difference in intradialytic hypertension between the groups according to all three definitions of intradialytic hypertension (p=0.134; 0.523; and 1, respectively).Conclusion: We found that iron sucrose administration does not cause both intradialytic hypotension and intradialytic hypertension.
- 21 January 2026
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 49 (2) , 126-132
Evaluation of the effect of sarcopenia and frailty on quality of life in older hemodialysis patients
Background: This study aimed to evaluate the impact of sarcopenia and frailty on the quality of life of older hemodialysis patients. Methods: Seventy hemodialysis patients aged ⩾60 years were assessed. Daily living activities (Katz Index), depression (Yesavage Scale), frailty (Fried’s Criteria), and sarcopenia (EWGSOP2) were evaluated. Quality of life was measured using the KDQOL-36 questionnaire. Results: The median age was 67 years, and 50% were female. Nineteen patients (27.1%) were partially dependent, 71.4% were pre-frail, and 15.7% were frail. Probable sarcopenia was detected in 77.1%, and sarcopenia in 8.6% of patients. Sarcopenia was associated with older age, higher dependency, depression, lower income, and frailty ( p < 0.05). It was also related to the KDQOL-36 physical component ( p = 0.031), while frailty correlated with the symptom component ( p = 0.047). Conclusion: Frailty and sarcopenia are common in older hemodialysis patients and adversely affect their quality of life.
- 21 January 2026
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 49 (2) , 126-132
Evaluation of the effect of sarcopenia and frailty on quality of life in older hemodialysis patients
Background: This study aimed to evaluate the impact of sarcopenia and frailty on the quality of life of older hemodialysis patients. Methods: Seventy hemodialysis patients aged ⩾60 years were assessed. Daily living activities (Katz Index), depression (Yesavage Scale), frailty (Fried’s Criteria), and sarcopenia (EWGSOP2) were evaluated. Quality of life was measured using the KDQOL-36 questionnaire. Results: The median age was 67 years, and 50% were female. Nineteen patients (27.1%) were partially dependent, 71.4% were pre-frail, and 15.7% were frail. Probable sarcopenia was detected in 77.1%, and sarcopenia in 8.6% of patients. Sarcopenia was associated with older age, higher dependency, depression, lower income, and frailty ( p < 0.05). It was also related to the KDQOL-36 physical component ( p = 0.031), while frailty correlated with the symptom component ( p = 0.047). Conclusion: Frailty and sarcopenia are common in older hemodialysis patients and adversely affect their quality of life.
- Open Access
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (1) , 67-71
The Relationship Between Mucociliary Clearance Time and Peritonitis Frequency in Patients Receiving Peritoneal Dialysis
Background: The present study sought to explore the association between nasal mucociliary clearance time (MCT) and the frequency of peritonitis among patients with chronic kidney disease (CKD) treated by peritoneal dialysis (PD). Methods: This cross-sectional study enrolled 24 patients with CKD treated by PD and 24 healthy volunteers. Nasal muco ciliary function was assessed using the saccharin transit time test. In this procedure, a saccharin particle with a 1 mm diameter was meticulously placed on the anteromedial surface of the inferior nasal concha. The 2 groups were compared based on their mean MCT. Within the patient group, the number of peritonitis cases in the last year was evaluated, and the correlation between MCT and the occurrence of peritonitis was analyzed. Results: The patient group consisted of 15 females and 9 males, with a mean age of 52.6 years. The control group included 14 females and 10 males, with a mean age of 47.5 years. The mean duration of PD among the followed cohort was 20 months, ranging from 3 to 190 months. The comparison of mean MCT between patients with a history of peritonitis and those with out peritonitis did not reveal a statistically significant difference (P = .333). However, the neutrophil-to-lymphocyte ratio was significantly elevated in the group exhibiting prolonged MCT (P = .046). Conclusion: Although this study found no statistically significant direct relationship between peritonitis incidence and MCT, the research aimed to evaluate MCT as a potential indicator of susceptibility to respiratory tract infections, which play a role in the development of peritonitis. Cite this article as: Doğan B, Ergül F, Basut R, et al. The relationship between mucociliary clearance time and peritonitis frequency in patients receiving peritoneal dialysis. Turk J Nephrol. 2026;35(1):67-71.
- 7 January 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Nephrology
- Vol. 35 (1) , 67-71
Open AccessThe Relationship Between Mucociliary Clearance Time and Peritonitis Frequency in Patients Receiving Peritoneal Dialysis
Background: The present study sought to explore the association between nasal mucociliary clearance time (MCT) and the frequency of peritonitis among patients with chronic kidney disease (CKD) treated by peritoneal dialysis (PD). Methods: This cross-sectional study enrolled 24 patients with CKD treated by PD and 24 healthy volunteers. Nasal muco ciliary function was assessed using the saccharin transit time test. In this procedure, a saccharin particle with a 1 mm diameter was meticulously placed on the anteromedial surface of the inferior nasal concha. The 2 groups were compared based on their mean MCT. Within the patient group, the number of peritonitis cases in the last year was evaluated, and the correlation between MCT and the occurrence of peritonitis was analyzed. Results: The patient group consisted of 15 females and 9 males, with a mean age of 52.6 years. The control group included 14 females and 10 males, with a mean age of 47.5 years. The mean duration of PD among the followed cohort was 20 months, ranging from 3 to 190 months. The comparison of mean MCT between patients with a history of peritonitis and those with out peritonitis did not reveal a statistically significant difference (P = .333). However, the neutrophil-to-lymphocyte ratio was significantly elevated in the group exhibiting prolonged MCT (P = .046). Conclusion: Although this study found no statistically significant direct relationship between peritonitis incidence and MCT, the research aimed to evaluate MCT as a potential indicator of susceptibility to respiratory tract infections, which play a role in the development of peritonitis. Cite this article as: Doğan B, Ergül F, Basut R, et al. The relationship between mucociliary clearance time and peritonitis frequency in patients receiving peritoneal dialysis. Turk J Nephrol. 2026;35(1):67-71.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (3) , e20251460
The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease
SUMMARY OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population. METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data. RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure. CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (3) , e20251460
Open AccessThe effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease
SUMMARY OBJECTIVE: The aim of this study was to evaluate the impact of sodium-glucose cotransporter-2 inhibitors on haematological parameters and other clinical markers in this patient population. METHODS: We retrospectively analyzed the medical records of 150 diabetic patients with chronic kidney disease who initiated sodium-glucose cotransporter-2 inhibitor therapy, comparing their baseline and 3-month post-treatment laboratory and clinical data. RESULTS: Following 3 months of treatment with sodium-glucose cotransporter-2 inhibitors, mean haemoglobin and haematocrit levels significantly increased, even in patients with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. This therapy also led to significant reductions in the spot urine albumin-to-creatinine ratio, as well as in both systolic and diastolic blood pressure. CONCLUSION: Sodium-glucose cotransporter-2 inhibitor therapy was associated with significant increases in haemoglobin and haematocrit levels in diabetic patients with chronic kidney disease. These findings suggest that sodium-glucose cotransporter-2 inhibitors may represent a potential area requiring further investigation for the treatment of anaemia associated with diabetic chronic kidney disease.
- 29 October 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (6) , 186-192
Assessing ciliary function in polycystic kidney disease: beyond the kidney
This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance. The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups. In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (p = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (p = 0.001). This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.
- 29 October 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (6) , 186-192
Assessing ciliary function in polycystic kidney disease: beyond the kidney
This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance. The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups. In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (p = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (p = 0.001). This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.
- 12 June 2025
- Published by Wiley in Therapeutic Apheresis and Dialysis
The Effect of Arteriovenous Fistula Creation on GFR Decline
Purpose: Chronic kidney disease (CKD) poses a significant public health challenge, severely affecting patients' quality of life. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend discussing renal replacement therapy options when patients reach CKD stage 4. Arteriovenous fistula (AVF) creation is considered the gold standard for vascular access in hemodialysis. This retrospective study aims to evaluate whether any changes in kidney function occur during the follow‐up period after AVF creation in patients with end‐stage kidney disease (ESKD).Methods: We analyzed data from 60 CKD patients who underwent AVF creation and were monitored in our nephrology outpatient clinics. Seventeen patients who consistently attended follow‐up visits were included for detailed analysis. We performed a retrospective review of laboratory and medical records from 6 months before and 6 months following AVF creation.Results: The cohort comprised 41.2% males, with a mean age of 62.4 years. The predominant underlying conditions were diabetes mellitus (58.8%), hypertension (29.4%), and polycystic kidney disease (11.8%). Statistical analysis of laboratory values before and after AVF creation (at 1, 3, and 6 months) revealed a significant decline in estimated glomerular filtration rate (eGFR) before AVF placement, followed by stabilization in the subsequent 6 months.Conclusion: The rate of eGFR decline was significantly reduced in CKD patients with AVF. This may be attributed to increased awareness of impending hemodialysis, leading to better dietary adherence and treatment compliance.
- 12 June 2025
- Published by Wiley in Therapeutic Apheresis and Dialysis
The Effect of Arteriovenous Fistula Creation on GFR Decline
Purpose: Chronic kidney disease (CKD) poses a significant public health challenge, severely affecting patients' quality of life. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend discussing renal replacement therapy options when patients reach CKD stage 4. Arteriovenous fistula (AVF) creation is considered the gold standard for vascular access in hemodialysis. This retrospective study aims to evaluate whether any changes in kidney function occur during the follow‐up period after AVF creation in patients with end‐stage kidney disease (ESKD).Methods: We analyzed data from 60 CKD patients who underwent AVF creation and were monitored in our nephrology outpatient clinics. Seventeen patients who consistently attended follow‐up visits were included for detailed analysis. We performed a retrospective review of laboratory and medical records from 6 months before and 6 months following AVF creation.Results: The cohort comprised 41.2% males, with a mean age of 62.4 years. The predominant underlying conditions were diabetes mellitus (58.8%), hypertension (29.4%), and polycystic kidney disease (11.8%). Statistical analysis of laboratory values before and after AVF creation (at 1, 3, and 6 months) revealed a significant decline in estimated glomerular filtration rate (eGFR) before AVF placement, followed by stabilization in the subsequent 6 months.Conclusion: The rate of eGFR decline was significantly reduced in CKD patients with AVF. This may be attributed to increased awareness of impending hemodialysis, leading to better dietary adherence and treatment compliance.
- 20 March 2025
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 48 (4) , 221
Reply “Comparison of the use of standard heparin and 0.9% saline as lock solution in hemodialysis catheters”
- 20 March 2025
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 48 (4) , 221
Reply “Comparison of the use of standard heparin and 0.9% saline as lock solution in hemodialysis catheters”
- 3 January 2025
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 48 (2) , 64-68
Comparison of the use of standard heparin and 0.9% saline as lock solution in hemodialysis catheter: Importance of closure technique
Background: Bleeding and thrombotic occlusion are complications of Central venous catheters. When selecting a catheter lock solution, factors such as bleeding, thrombotic occlusion, infection, and cost-effectiveness must be considered. Methods: The study included 35 patients who used heparin as a locking solution and 35 patients who used 0.9% saline, retrospectively. In our center, after injecting the solution equal to the catheter lumen volume from the syringe, approximately 1 cc of locking solution is left in the syringe, the catheter is locked and the syringe is removed from the catheter after locking. Intergroup complications were observed. Results: No significant difference was observed between the groups concerning the catheter insertion site ( p = 0.143 and 0.143). Additionally, no significant differences were found between the groups in terms of thrombosis and bleeding complications ( p = 0.314 and 0.239, respectively). Conclusion: Our study concluded that heparin locking is not superior to normal saline locking in terms of catheter dysfunction. We aimed to emphasize that the technique of catheter locking is more important than the type of lock solution used.
- 3 January 2025
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 48 (2) , 64-68
Comparison of the use of standard heparin and 0.9% saline as lock solution in hemodialysis catheter: Importance of closure technique
Background: Bleeding and thrombotic occlusion are complications of Central venous catheters. When selecting a catheter lock solution, factors such as bleeding, thrombotic occlusion, infection, and cost-effectiveness must be considered. Methods: The study included 35 patients who used heparin as a locking solution and 35 patients who used 0.9% saline, retrospectively. In our center, after injecting the solution equal to the catheter lumen volume from the syringe, approximately 1 cc of locking solution is left in the syringe, the catheter is locked and the syringe is removed from the catheter after locking. Intergroup complications were observed. Results: No significant difference was observed between the groups concerning the catheter insertion site ( p = 0.143 and 0.143). Additionally, no significant differences were found between the groups in terms of thrombosis and bleeding complications ( p = 0.314 and 0.239, respectively). Conclusion: Our study concluded that heparin locking is not superior to normal saline locking in terms of catheter dysfunction. We aimed to emphasize that the technique of catheter locking is more important than the type of lock solution used.